GSK PLC closed 25.31% below its 52-week high of £18.24, which the company reached on May 16th.

Rating upgraded from 66 to 73 Tuesday — a welcome improvement, but still shy of the 80 or better score you prefer to see.

Many novel drugs are more relevant for subspecialists, but of the six first-in-class medications approved by the US Food and ...

GSK’s Blenrep is the only B-cell maturation antigen (BCMA)-targeted antibody-drug conjugate for multiple myeloma, offering ...

Roche has pledged to build a giant weight-loss drug factory in the US. The plans form part of a $50bn (£37bn) pledge aimed at ...

This FTSE 100 firm's smaller than rivals but could benefit from its big US manufacturing footprint and competitive market ...

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has authorised GSK’s Blenrep for treating multiple ...

GSK plc (LSE/NYSE: GSK) has today released global survey data showing that over half (52%) of people aged 50-60 feel younger ...

The Argus analysis shows the People’s Bank of China holds a £2.4bn stake in Shell and £1bn in AstraZeneca, while China ...

China’s response to new United States (U.S.) tariffs could complicate the supply of important medicines, an analysis of data ...

GSK plc has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised Blenrep. In the UK, ...

GSK plc has announced that the Advisory Committee on Immunization Practices (ACIP) voted in favour of recommending the use of RSV vaccines including GSK’s Arexvy (Respiratory Syncytial ...